Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
Blood|December 14, 2004
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkMartin Dreyling, Georg Lenz, Eva Hoster, et al.
Haematologica|December 26, 2015
Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA studyMorgane Cheminant, Coralie Derrieux, Aurore Touzart, et al.
European Journal of Endocrinology|June 26, 2025
Mitotane treatment of adrenocortical carcinoma induces tumoural secretion of GDF-15: impact on poor prognosis and impaired responsiveness to immunotherapyIsabel Weigand, Alexandra S Triebig, Tanja Maier, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|October 27, 2007
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Martin Dreyling, Wolfram Klapper, et al.
Leukemia & Lymphoma|October 2, 2012
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Leukemia|July 7, 2026
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histologyJonas Lippl, Sarah Reinke, Karoline Koch, et al.
Blood|January 29, 2021
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcomeLorenz Thurner, Natalie Fadle, Jörg Thomas Bittenbring, et al.
Hemasphere|November 15, 2019
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR StudyKlaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Pageof 11